Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 and Fluconazole Interaction Study
NCT04871724Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zelicapavir in respiratory syncytial virus infection (RSV), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration up to 19 days and Area Under the Plasma Concentration-Time Curve up to 19 days. Started Mar 2021; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04871724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871724.